Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Advances in Bioprinting: From Tissue Engineering to Neuro Research
Biotech & Bioprocessing Advances in Bioprinting: From Tissue Engineering to Neuro Research

Bioprinting has emerged as a revolutionary bioengineering technique that utilizes the principles of 3D printing to create tissue-like structures embedded with living cells. Since its inception in 1988, this technology has experienced tremendous growth, advancing from its original concept to today’s

Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs
Research & Development Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs

The recent halt of life-saving drug trials due to an unanticipated funding freeze by the U.S. government has created significant uncertainty and disruption in the fight against malaria, a disease that remains a major global health threat. This decision, stemming from an initiative by the Trump

Nematode's 46,000-Year Survival Explores Limits of Life and Science
Biotech & Bioprocessing Nematode's 46,000-Year Survival Explores Limits of Life and Science

The discovery of a nematode, known as Panagrolaimus kolymaensis, unearthed from the depths of the Siberian permafrost has astonished scientists. This microscopic worm managed to survive in a state of cryptobiosis for an astounding 46,000 years. Over this period, it remained suspended in a

Can Danaher Lead the Biopharma Sector With Innovations and Biosimilars?
Biotech & Bioprocessing Can Danaher Lead the Biopharma Sector With Innovations and Biosimilars?

As the landscape of biopharmaceutical manufacturing undergoes significant changes, Danaher Corporation stands at a pivotal crossroads with the potential to lead through its innovative strategies and products. At the TD Cowen Health Care Conference, Danaher President and CEO Rainer Blair emphasized

Are New Zealand's Health Data Protection Measures Sufficient Enough?
Management & Regulatory Are New Zealand's Health Data Protection Measures Sufficient Enough?

When a routine investigation by New Zealand authorities revealed alarming gaps in the protocols for managing health data, the country found itself grappling with an urgent and complex challenge. In an era where data breaches are becoming increasingly frequent and sophisticated, the protection of

Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial
Research & Development Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial

The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can

Can Ecopipam Be the Breakthrough Treatment for Tourette Syndrome?
Research & Development Can Ecopipam Be the Breakthrough Treatment for Tourette Syndrome?

Emalex Biosciences recently shared tremendous news regarding their latest breakthrough in the treatment of Tourette syndrome. The company announced promising topline results from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor antagonist. This milestone could position

Ecopipam Nears FDA Approval for Tourette Syndrome Treatment
Tech & Innovation Ecopipam Nears FDA Approval for Tourette Syndrome Treatment

Tourette syndrome is a complex condition marked by involuntary motor and vocal tics, significantly impacting the lives of those affected. For years, the medical community has struggled to find an effective treatment that targets the root cause of these symptoms. This struggle has led to the

Can Gene Therapy DB-OTO Revolutionize Treatment for Genetic Hearing Loss?
Tech & Innovation Can Gene Therapy DB-OTO Revolutionize Treatment for Genetic Hearing Loss?

In this interview, we are pleased to welcome Ivan Kairatov, a Biopharma expert with deep knowledge of tech and innovation in the industry and extensive experience in research and development, particularly in gene therapy for sensory disorders. Today, Ivan will share insights on the recent positive

Can Telehealth and PCPs Revolutionize Advanced Diabetes Care Access?
Tech & Innovation Can Telehealth and PCPs Revolutionize Advanced Diabetes Care Access?

Ivan Kairatov is a Biopharma expert, with profound knowledge in technology and innovation in the medical industry, and extensive experience in research and development. Today, we'll delve into a study from the University of Colorado Anschutz Medical Campus, discussing its significance for

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later